Medicis Pharmaceutical Corp. (MRX) Misses Q3 EPS by 5c; Guides Q4 EPS Below Views
Tweet
Share
E-mailGet Alerts MRX Hot Sheet
Price: $72.99 +4.89%
Financial Fact:
Interest Expense: 7.16M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Interest Expense: 7.16M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Medicis Pharmaceutical Corp. (NYSE: MRX) reported Q3 EPS of $0.56, $0.05 worse than the analyst estimate of $0.61. Revenue for the quarter came in at $184.7 million versus the consensus estimate of $187.06 million.
Sees Q4 2011 EPS of $0.63-$0.69, versus the consensus of $0.70. Sees Q4 2011 revenue of $187-$200 million, versus the consensus of $199 million.
Sees Q4 2011 EPS of $0.63-$0.69, versus the consensus of $0.70. Sees Q4 2011 revenue of $187-$200 million, versus the consensus of $199 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
- TJX Cos. (TJX) Tops Q2 EPS by 3c, Beats on Revenue; Offers FY27 EPS Guidance
- Deere & Co. (DE) Tops Q3 EPS by 41c, raises guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
